
Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More


Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

Comprehensive sequencing is now an essential checkpoint at every stage in drug development — discover how Oxford Nanopore sequencing can support the development of your cell, gene, and RNA therapy drug modalities. In this Guide, you will learn: How nanopore sequencing enables whole plasmid characterisation, delivering complete confidence in your… Read More

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW. This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers. The top stories: … Read More

DDW’s Maria Wallace attended Cancer Research Horizons’ On the Horizon breakfast event to learn more about the latest opportunities and challenges in cancer drug discovery and development. Leading experts from academia, pharma, biotech and investment met in London, UK Thursday 11 June to discuss the potential of in vivo CAR-T therapies to transform the future of… Read More

DaltonTx has launched an AI drug discovery platform which could help scientists “make better-informed decisions earlier in the discovery process”. The platform, called Dalton, seeks to integrate agentic AI, human expertise and experimental data into a continuous learning engine. DaltonTx says the platform links molecules, assays, models, experimental outcomes, project context and human decisions… Read More

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

Bead BioPharma has emerged from stealth by submitting a patent for a novel cancer drug platform. The life sciences company, backed by Archangels, submitted the patent in efforts to launch its formal entry into one of the most competitive sectors of global oncology. Bead BioPharma is focused on antibody-drug conjugates (ADCs), a class of cancer therapies sometimes… Read More

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

Dr Joe Renny, Head of Corporate Development, and Dr Simon Tyler, Chief Commercial Officer, CatSci, discuss the last 15 years of drug development, and what comes next. The American Cancer Society’s 2026 statistics tell a story that should be on the wall of every drug developer. Five-year survival for chronic… Read More

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More